DR DANIEL DÍAZ TORRADO & DR FERNANDO SILIKOVICH
Two internationally recognised aesthetic physicians analyse how the second generation of mesofiller® nexha redefines the concept of dermal fillers by combining immediate structural correction with true, long-term tissue regeneration.
A new injectable paradigm presented at IMCAS Paris
Presented during mesoestetic®’s official symposium at IMCAS Paris, the second generation of mesofiller® nexha introduces a ground-breaking approach to injectable treatments. Far beyond conventional volumisation, this advanced filler range has been developed to integrate structural support and active bioestimulation in a single injectable solution. The new range is structured around indication-oriented solutions, including mesofiller® nexha aox, aimed at improving luminosity and treating mild wrinkles, and mesofiller® nexha lift, designed for non-surgical lifting, tissue repositioning and global revitalisation.
ANTI-AGE & LONGEVITY MAGAZINE: The symposium focused on breaking the aesthetic status quo. How does the second generation of mesofiller® nexha represent a paradigm shift towards regenerative, biology-driven aesthetic medicine?
DOCTOR DANIEL DÍAZ TORRADO: Until recently, injectable treatments were clearly divided into two separate categories: cross-linked hyaluronic acid fillers, focused on immediate volumetric correction, and biostimulators, designed to gradually improve tissue quality. The second generation of mesofiller® nexha breaks with this long-standing paradigm. It is not just a biocompatible filler, but a biologically active injectable capable of delivering immediate aesthetic correction while simultaneously activating long-term bioestimulation and tissue regeneration.
AA&LM: From a clinical perspective, in which patient profiles do you find mesofiller® nexha aox and mesofiller® nexha lift particularly effective?
DOCTOR FERNANDO SILIKOVICH: mesofiller® nexha aox is especially effective in patients with fine to mild wrinkles, superficial depressions associated with hyperpigmentation, and irregular skin texture—profiles commonly seen in smokers or individuals exposed to high oxidative stress. In contrast, mesofiller® nexha lift is particularly suited for patients presenting early signs of laxity and flaccidity, where the objective is to achieve a lifting and tightening effect without adding volume, thereby preserving natural facial architecture. In these cases, the combination of NCTC 109 and DMAE provides a global revitalising effect that enhances tissue tone and firmness.
AA&LM: During the symposium, you both presented clinical cases. What is the key differential value of mesofiller® nexha in your daily practice?
DR. F.S: As demonstrated during the symposium, the strategic combination of mesofiller® nexha volume and mesofiller® nexha lift allowed me to achieve optimal facial harmonisation with a more predictable evolution over time, while even reducing the total injected volume—from 6 ml to 5 ml. This efficiency, combined with long-term tissue improvement, is a major clinical advantage.
DR. D.D.T: In my practice, particularly in facial masculinisation where higher volumes of hyaluronic acid are often required, I need a product that offers structural performance without inducing excessive inflammation, ensuring both efficacy and a high safety profile. mesofiller® nexha delivers exactly that. Moreover, its capacity to progressively improve skin quality over time represents a significant added value that clearly differentiates this new generation from conventional fillers.
DR DANIEL DÍAZ TORRADO
Aesthetic physician, international trainer, founder of KDK Academy, and creator of the 10/10 technique.
DR FERNANDO SILIKOVICH
Creator of the 4 Points® concept, with more than 20 years’ experience in aesthetic medicine.
